Vertex Plans To Provide Access To Potential CF Therapy VX-770 For Patients With Critical Medical Need
Originally posted in Cystic Fibrosis News From Medical News Today
Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug from the U.S. Food and Drug Administration (FDA)…
No Comments »
RSS feed for comments on this post. TrackBack URL
by Raelene
